Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Patients with CLL and partial response to venetoclax-obinutuzumab

Othman Al-Sawaf • 12 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Antibodies Obinutuzumab Venetoclax

Othman Al-Sawaf, MD, of the University Hospital of Cologne, Cologne, Germany, highlights characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) showing partial response to venetoclax-obinutuzumab. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Othman Al-Sawaf

CLL17 trial: fixed-duration vs continuous targeted treatment for previously untreated CLL
9:23
CLL17 trial: fixed-duration vs continuous targeted treatment for previously untreated CLL
Othman Al-Sawaf • 6 Dec 2025
Treatment of Richter’s transformation: recent insights
1:47
Treatment of Richter’s transformation: recent insights
Othman Al-Sawaf • 16 Jun 2023
The expanding landscape of next-generation BTK inhibitors in CLL
1:26
The expanding landscape of next-generation BTK inhibitors in CLL
Othman Al-Sawaf • 16 Jun 2023
Fixed-duration treatment strategies for frontline and relapsed CLL
0:56
Fixed-duration treatment strategies for frontline and relapsed CLL
Othman Al-Sawaf • 16 Jun 2023

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Othman Al-Sawaf • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Othman Al-Sawaf • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Othman Al-Sawaf • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Othman Al-Sawaf • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals